A herb extract of *Gnaphalium affine*, its preparation method and application

By optimizing the extraction process of *Gnaphalium affine* extract, and using a mixture of ethyl acetate/ethanol solution and ammonia treatment combined with macroporous resin chromatography, the problems of low dissolution of active ingredients and safety hazards in existing technologies have been solved, achieving efficient and safe large-scale production and excellent therapeutic effects.

CN117982480BActive Publication Date: 2026-11-10CHINA STATE INST OF PHARMA IND CO LTD +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410162192.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-02-05
Publication Date
2026-11-10
Estimated Expiration
2044-02-05

AI Technical Summary

Technical Problem

Existing extracts of Gnaphalium affine have low solubility of active ingredients, limited scalability and repeatability of extraction processes, and use large amounts of solvents with poor blast resistance, such as petroleum ether and ethyl acetate, posing safety hazards.

Method used

A novel extraction method was employed, including treatment with an ethyl acetate/ethanol mixture and ammonia, combined with macroporous resin chromatography, to optimize the extraction process, improve the dissolution rate of active ingredients, and reduce the use of petroleum ether and ethyl acetate.

Benefits of technology

The dissolution rate of active ingredients was increased to 92.56%, which enhanced the therapeutic effect on chronic hyperuricemia and hyperuricemic nephropathy, ensured the stability of active ingredient content in large-scale production of the extract, and significantly reduced production safety hazards.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117982480B_ABST
    Figure CN117982480B_ABST
Patent Text Reader

Abstract

This invention discloses an extract of *Gnaphalium affine*, its preparation method, and its application. This invention also provides a pharmaceutical composition comprising the following active ingredients in the indicated mass fractions: 0.1-0.3% chlorogenic acid, 0.01-0.15% caffeic acid, 6-9% 4'-hydroxy-5-methoxy-7-O-β-D-glucopyranosyl dihydroflavonoid, 9-14% 1,5-O-dicaffeoylquinic acid, 10-15% 3,5-O-dicaffeoylquinic acid, 3.5-5% luteolin-4'-glucoside, 2.5-4% 4,5-O-dicaffeoylquinic acid, 0.01-0.2% 1,3,5-O-tricaffeoylquinic acid, 1-2% luteolin, and 8-12% 1,3,4-O-tricaffeoylquinic acid. The active ingredients in the *Gnaphalium affine* extract provided by this invention have high total dissolution rate, excellent therapeutic effect on chronic hyperuricemia and hyperuricemic nephropathy, and high bioavailability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a cudweed extract, its preparation method, and its application. Background Technology

[0002] Chinese patent CN114053321A discloses an active composition selected based on its uric acid-lowering activity. This composition is prepared by extracting Gnaphalium affine extract and combining the ethyl acetate phase and the n-butanol phase. The composition has the effects of lowering uric acid (promoting uric acid excretion and inhibiting uric acid production), protecting the kidneys, and protecting the liver (Liu F, Liu XZ, Yang Q, et al. Enhanced Efficacy and Reduced Hepatotoxicity by Combination of Gnaphalium affine Extract and Benzbromarone in the Treatment of Rats with Hyperuricemic Nephropathy[J]. Pharmaceutical Fronts, 2021, 03(03):e129–e137). Its main active ingredients are flavonoids (glycosides), caffeic acid, and caffeic acid derivatives (monocaffeoylquinic acid, di- and tri-caffeoylquinic acid, caffeic acid glucose ester, caffeic acid methyl / ethyl ester, etc.).

[0003] However, existing Gnaphalium affine extracts have the following shortcomings: (1) the dissolution rate of active ingredients in the extract is low; (2) the scale-up and reproducibility of the extraction process are limited (for feed of less than 5 kg of medicinal material, the active ingredient content of the extract is about 50%; for feed of more than 5 kg of medicinal material, the active ingredient content of the extract is only about 30%); (3) the extraction process uses a large amount of solvents with poor anti-explosion properties, such as petroleum ether and ethyl acetate, which poses a significant safety hazard in scale-up production. Summary of the Invention

[0004] To address the problems of existing technologies (1) low dissolution rate of active ingredients in extracts, (2) inability to reduce the content of *Gnaphalium affine* composition after process scale-up, and (3) use of large amounts of solvents with poor anti-explosion properties (petroleum ether, ethyl acetate), this application provides a pharmaceutical composition. The pharmaceutical composition of this invention has one or more of the following advantages: (1) the dissolution rate of active ingredients in the pharmaceutical composition of this invention is 92.56%, which is 2.6 times higher than that of existing technologies; (2) it has excellent therapeutic effects on chronic hyperuricemia and hyperuricemic nephropathy, improving the bioavailability of active compounds; (3) after process scale-up, the content of active ingredients in *Gnaphalium affine* extract obtained by the extraction method of the pharmaceutical composition is still above 50% (m / m), with good reproducibility, suitable for large-scale production; (4) petroleum ether is not used in the preparation of the pharmaceutical composition of this application, and the amount of ethyl acetate is reduced by 80% to 99.6%, significantly reducing production safety hazards. This invention mainly solves the above-mentioned technical problems through the following technical solutions.

[0005] This invention discloses a pharmaceutical composition comprising the following active ingredients in weight fractions: 0.1-0.3% chlorogenic acid, 0.01-0.15% caffeic acid, 6-9% 4'-hydroxy-5-methoxy-7-O-β-D-glucopyranosyl dihydroflavone, 9-14% 1,5-O-dicaffeoylquinic acid, 10-15% 3,5-O-dicaffeoylquinic acid, 3.5-5% luteolin-4'-glucoside, 2.5-4% 4,5-O-dicaffeoylquinic acid, 0.01-0.2% 1,3,5-O-tricaffeoylquinic acid, 1-2% luteolin, and 8-12% 1,3,4-O-tricaffeoylquinic acid.

[0006] In some embodiments, the chlorogenic acid has a mass fraction of 0.125-0.221%, for example 0.125%, 0.22%, or 0.221%.

[0007] In some embodiments, the caffeic acid has a mass fraction of 0.04-0.101%, for example, 0.04%, 0.086%, or 0.101%.

[0008] In some embodiments, the 4'-hydroxy-5-methoxy-7-O-β-D-glucopyranosyl dihydroflavone has a mass fraction of 7.33%-7.97%, for example 7.33%, 7.34% or 7.97%.

[0009] In some embodiments, the mass fraction of the 1,5-O-dicaffeoylquinic acid is 11.31-12.1%, for example 11.31%, 11.72%, or 12.1%.

[0010] In some embodiments, the mass fraction of the 3,5-O-dicaffeoylquinic acid is 11.72-14.4%, for example 11.725%, 12.17%, or 14.4%.

[0011] In some embodiments, the mass fraction of luteolin-4'-glucoside is 4.08-4.51%, for example 4.08%, 4.15%, or 4.51%.

[0012] In some embodiments, the mass fraction of the 4,5-O-dicaffeoylquinic acid is 3.07-3.42%, for example 3.07%, 3.19%, or 3.42%.

[0013] In some embodiments, the mass fraction of the 1,3,5-O-tricaffeoylquinic acid is 0.05%-0.15%, for example, 0.1%.

[0014] In some embodiments, the mass fraction of luteolin is 1.5-1.897%, for example 1.5%, 1.58%, or 1.897%.

[0015] In some embodiments, the mass fraction of the 1,3,4-O-tricaffeoylquinic acid is 10.07-10.45%, for example 10.07%, 10.13%, or 10.45%.

[0016] In some embodiments, the active ingredient content of the pharmaceutical composition is 50%-70%, such as 50.156%, 52.105%, or 52.939%.

[0017] In some embodiments, the active ingredient of the pharmaceutical composition comprises 0.1-0.3% chlorogenic acid, 0.04-0.101% caffeic acid, 6-8% 4'-hydroxy-5-methoxy-7-O-β-D-glucopyranosyl dihydroflavone, 9-14% 1,5-O-dicaffeoylquinic acid, 10-15% 3,5-O-dicaffeoylquinic acid, 3.5-5% luteolin-4'-glucoside, 2.5-4% 4,5-O-dicaffeoylquinic acid, 0.01-0.2% 1,3,5-O-tricaffeoylquinic acid, 1-2% luteolin, and 8-12% 1,3,4-O-tricaffeoylquinic acid.

[0018] In some embodiments, the active ingredient of the pharmaceutical composition comprises 0.1-0.3% chlorogenic acid, 0.125-0.221% caffeic acid, 7.33%-7.97% 4'-hydroxy-5-methoxy-7-O-β-D-glucopyranosyl dihydroflavone, 11.31-12.1% 1,5-O-dicaffeoylquinic acid, 11.72-14.4% 3,5-O-dicaffeoylquinic acid, 4.08-4.51% luteolin-4'-glucoside, 3.07-3.42% 4,5-O-dicaffeoylquinic acid, 0.1% 1,3,5-O-tricaffeoylquinic acid, 1.5-1.897% luteolin, and 10.07-10.45% 1,3,4-O-tricaffeoylquinic acid.

[0019] In some embodiments, the pharmaceutical composition is further preferably Scheme 1, Scheme 2, or Scheme 3;

[0020] Option 1: The active ingredients of the pharmaceutical composition consist of 0.22% chlorogenic acid, 0.086% caffeic acid, 7.34% 4'-hydroxy-5-methoxy-7-O-β-D-glucopyranosyl dihydroflavone, 11.72% 1,5-O-dicaffeoylquinic acid, 11.72% 3,5-O-dicaffeoylquinic acid, 4.15% luteolin-4'-glucoside, 3.19% 4,5-O-dicaffeoylquinic acid, 0.1% 1,3,5-O-tricaffeoylquinic acid, 1.5% luteolin, and 10.13% 1,3,4-O-tricaffeoylquinic acid.

[0021] Option 2: The active ingredients of the pharmaceutical composition consist of 0.125% chlorogenic acid, 0.04% caffeic acid, 7.33% 4'-hydroxy-5-methoxy-7-O-β-D-glucopyranoside dihydroflavone, 11.31% 1,5-O-dicaffeoylquinic acid, 14.40% 3,5-O-dicaffeoylquinic acid, 4.08% luteolin-4'-glucoside, 3.07% 4,5-O-dicaffeoylquinic acid, 0.1% 1,3,5-O-tricaffeoylquinic acid, 1.58% luteolin, and 10.07% 1,3,4-O-tricaffeoylquinic acid.

[0022] Option 3: The active ingredients of the pharmaceutical composition consist of 0.221% chlorogenic acid, 0.101% caffeic acid, 7.97% 4'-hydroxy-5-methoxy-7-O-β-D-glucopyranosyl dihydroflavone, 12.10% 1,5-O-dicaffeoylquinic acid, 12.17% 3,5-O-dicaffeoylquinic acid, 4.51% luteolin-4'-glucoside, 3.42% 4,5-O-dicaffeoylquinic acid, 0.1% 1,3,5-O-tricaffeoylquinic acid, 1.897% luteolin, and 10.45% 1,3,4-O-tricaffeoylquinic acid.

[0023] In some embodiments, the pharmaceutical composition is prepared by a method comprising the following steps:

[0024] S1. Filter the ethyl acetate / ethanol mixture of crude cudweed extract to obtain a primary filtrate;

[0025] S2. Mix the filtered material with ammonia water, filter to obtain a secondary filtrate, and dry the secondary filtrate to obtain a pharmaceutical composition.

[0026] The active ingredient content of the crude cudweed extract is 25-27%.

[0027] In some embodiments, in S1, the volume ratio of ethyl acetate to ethanol in the ethyl acetate / ethanol mixed solution is 0.5:1-5:1, preferably 1:1-4:1, for example 1:1, 2:1 or 4:1.

[0028] In some embodiments, in S1, the concentration of the ethyl acetate / ethanol mixture of the crude extract of *Gnaphalium affine* is 0.005-1.5 kg / L, preferably 0.01-1 kg / L, for example 0.01 kg / L, 0.1 kg / L or 1 kg / L.

[0029] In some embodiments, in S1, the ethyl acetate / ethanol mixed solution of the crude extract of Gnaphalium affine is prepared by the following method, which includes the following specific steps: take the crude extract of Gnaphalium affine, first add ethyl acetate, mix well, then add ethanol, and mix well again.

[0030] In some embodiments, in S2, the ammonia water is commercially available analytical grade, wherein the mass fraction of NH3·H2O is 25-28%.

[0031] In some embodiments, in S2, the volume percentage of the ammonia water to the primary filtrate is 0.03-0.3%, preferably 0.05-0.2%, for example 0.05%, 0.15% or 0.2%.

[0032] In some embodiments, in S2, the pH of the secondary filtrate is 3-4, preferably 3.3-3.6, such as 3.3, 3.4, 3.6.

[0033] In some embodiments, the crude extract of *Gnaphalium affine* is prepared by a method comprising the following steps:

[0034] The concentrated extract of the ethanol-water solution of centrifuged gnaphalium affine was obtained, and the supernatant was purified by column chromatography and dried.

[0035] The volume content of ethanol in the ethanol-water solution can be the volume content of ethanol in ethanol-water solutions commonly used in the art, for example, 50%-80%, preferably 60%.

[0036] In some embodiments, the ethanol-water extract of Gnaphalium affine is obtained by extracting Gnaphalium affine with an ethanol-water solution, and the extraction operation and conditions can be conventional in the art.

[0037] The mass-to-volume ratio of the *Gnaphalium affine* to the ethanol aqueous solution can be the same as the ratio of raw material to solvent used in conventional phytochemical extraction, preferably 1:10 to 1:20 kg / L, and more preferably 1:10 to 1:15 kg / L.

[0038] Preferably, the extraction temperature is 80–130°C, more preferably 90–120°C, and even more preferably 90–100°C.

[0039] The extraction is performed 2 to 4 times, more preferably 3 to 4 times.

[0040] In the extraction process, the extraction time for a single extraction is preferably 1 to 2 hours.

[0041] In some embodiments, the concentrate is obtained by concentrating an ethanol-water extract of Gnaphalium affine, and the concentration operation and conditions are conventional in the art, generally vacuum concentration.

[0042] Preferably, the temperature for vacuum concentration is 50–70°C, for example, 60°C.

[0043] In some embodiments, the mass-to-volume ratio of the cudweed to the concentrate is 0.3 to 1.3 kg / L, more preferably 0.5 to 1.0 kg / L, for example 0.5 kg / L, 0.7 kg / L or 1.0 kg / L.

[0044] The centrifugation can be carried out at conventional centrifugation speeds in the art, such as 2000-8000 rpm, preferably 3000-6000 rpm, for example 3000 rpm, 4000 rpm or 6000 rpm.

[0045] The centrifugation can be performed using conventional centrifugation times in the art, such as 5-30 min, preferably 10-20 min, for example 10 min, 15 min or 20 min.

[0046] In some embodiments, the column chromatography uses macroporous resin LS305 for column packing.

[0047] In some embodiments, the column chromatography uses an aqueous solution of organic acid for impurity removal.

[0048] In some embodiments, the column chromatography involves eluting with an aqueous ethanol solution to obtain an eluent.

[0049] In some embodiments, the mass-to-volume ratio of the cudweed to the chromatography column is 1-2.5 kg / L, for example, 1.1-2.1 kg / L.

[0050] In some embodiments, the macroporous resin LS305 is a water-soaked macroporous resin LS305.

[0051] In some embodiments, the supernatant loading flow rate is 0.3-1 column volume / h, preferably 0.5 column volume / h.

[0052] In some embodiments, the aqueous organic acid solution is an aqueous formic acid solution or an aqueous acetic acid solution, preferably an aqueous formic acid solution.

[0053] In some embodiments, the volume content of the organic acid in the aqueous organic acid solution is 0.3%-0.7%, for example, 0.5%.

[0054] In some embodiments, the volume of the organic acid aqueous solution is 3-12 times the column volume, for example 5-10 times the column volume.

[0055] In some embodiments, the flow rate of the organic acid aqueous solution for impurity removal is 0.6-1.4 column volumes / h, preferably 1 column volume / h.

[0056] In some embodiments, the volume content of ethanol in the aqueous ethanol solution is 50%-80%, preferably 60%.

[0057] In some embodiments, the volume of the ethanol-water solution is 3-12 times the column volume, for example 5-10 times the column volume.

[0058] In some embodiments, the elution flow rate of the ethanol-water solution is 0.6-1.4 column volumes / h, preferably 1 column volume / h.

[0059] The present invention also provides a method for purifying a pharmaceutical composition, wherein the conditions and operations are as described above.

[0060] The present invention also provides a pharmaceutical formulation comprising the aforementioned pharmaceutical composition and acceptable pharmaceutical excipients.

[0061] In some implementations, the pharmaceutical excipient includes lactose.

[0062] In some embodiments, the mass ratio of the pharmaceutical composition to the lactose is 1:1 to 1:5, preferably 1:1 to 1:3, for example 1:1, 1:2 or 1:3.

[0063] In some embodiments, the pharmaceutical preparation is an oral granule formulation.

[0064] In some embodiments, the pharmaceutical preparation is prepared by mixing the pharmaceutical composition, lactose, and a humectant, sieving, and drying.

[0065] In some embodiments, the wetting agent is a 50%-90% aqueous ethanol solution, preferably a 60%-80% aqueous ethanol solution.

[0066] In some embodiments, the mass ratio of the pharmaceutical composition to the wetting agent is 5-15%.

[0067] The present invention also provides the use of the pharmaceutical composition or pharmaceutical preparation described above in the preparation of a medicament for treating chronic hyperuricemia or hyperuricemic nephropathy.

[0068] In some embodiments, the daily dose of the pharmaceutical composition is (8 mg / kg) (i.e., (560 mg) for a 70 kg adult).

[0069] In some embodiments, the daily dose of the pharmaceutical preparation for a 70kg adult is 1-3g / day, preferably 1.1-2.2g / day, for example 1.1g / day, 1.7g / day or 2.2g / day.

[0070] Based on common knowledge in the field, the above-mentioned preferred conditions can be combined arbitrarily to obtain various preferred embodiments of the present invention.

[0071] The reagents and raw materials used in this invention are all commercially available.

[0072] The positive and progressive effects of the pharmaceutical composition of the present invention are as follows:

[0073] (1) The dissolution rate of the active ingredient in the pharmaceutical composition of the present invention is 92.56%, which is 2.6 times higher than that of the prior art;

[0074] (2) It has excellent therapeutic effects on chronic hyperuricemia and hyperuricemic nephropathy, and improves the bioavailability of active compounds;

[0075] (3) The extraction method of the drug composition, after scale-up, still yields an active ingredient content of more than 50% (m / m) in the extract of Gnaphalium affine, with good reproducibility and suitable for large-scale production;

[0076] (4) No petroleum ether was used in the preparation of the pharmaceutical composition of this application, and the amount of ethyl acetate was reduced by 80% to 99.6%, which significantly reduced the production safety risks. Attached Figure Description

[0077] Figure 1The image shows the UHPLC (280nm) spectrum of the extract of *Gnaphalium affine* and the peak elution of its active ingredients. Detailed Implementation

[0078] The present invention is further illustrated below by way of embodiments, but the invention is not limited to the scope of the embodiments described herein. Experimental methods in the following embodiments that do not specify specific conditions were performed according to conventional methods and conditions, or as selected according to the product instructions.

[0079] Methods for determining the content of cudweed extract:

[0080] High-performance liquid chromatography (HPLC) was used for detection. A Thermo Vanquish ultra-high-performance liquid chromatograph (UPLC) with a WatersAcquity UPLC HSS T3 column (2.1 mm × 150 mm, 1.8 μm) was used. Gradient elution was performed using 0.1% formic acid (A)-acetonitrile (B) as the mobile phase. Elution conditions were: 0–9 min 8–13% B; 9–17 min 22–25% B; 17–25 min 25–50% B; 25–27 min 50–80% B; 27–35 min 90% B; 35–40 min 8% B. The detection time was 40 min, the column temperature was 40 °C, the detection wavelength was 280 nm, the flow rate was 0.3 mL / min, and the injection volume was 1 μL.

[0081] Example 1

[0082] After being dried in the shade, *Gnaphalium affine* (origin: Quzhou, Zhejiang) was cut into sections, and 40 kg was weighed out. This was mixed with a 60% (v / v) ethanol aqueous solution, with a herb-to-solvent mass-to-volume ratio of 1:15 (kg / L). The mixture was heated to 90℃ and refluxed four times, each time for 2 hours. The extracts were combined. The extract was then concentrated under reduced pressure at 60℃ to 80 L (0.5 kg crude herb / L) to obtain a concentrated solution. The concentrated solution was centrifuged at 3000 rpm for 20 minutes, the precipitate was discarded, and the supernatant was collected.

[0083] The macroporous resin LS305, soaked in water, was packed into a column (18×144cm, approximately 35L per column). The supernatant was loaded onto the column at a flow rate of 0.5 column volumes / h until complete, and the eluent was discarded. Then, the column was eluted with 5 column volumes of 0.05% (v / v) formic acid aqueous solution at a flow rate of 1 column volume / h to remove impurities, and the resulting eluent was discarded. The column was then eluted with 5 column volumes of 60% (v / v) ethanol aqueous solution at a flow rate of 1 column volume / h, and the eluent was collected. The eluent was concentrated by vacuum distillation and dried to obtain 1362.2g of resin eluent.

[0084] Take the above resin eluent, add ethyl acetate first at a ratio of 4:1 of ethyl acetate to ethanol, shake and mix well, then add ethanol, the total material-to-liquid ratio is 0.1 kg / L, shake and mix again, filter to obtain a first filtrate, then add ammonia water to the first filtrate so that the volume percentage of ammonia water to the first filtrate is 0.15%, shake and mix well, filter, the pH of the filtrate is 3.6, concentrate the filtrate under reduced pressure, dry, and obtain 415.8 g of Gnaphalium affine extract.

[0085] The active ingredients of the cudweed extract in Example 1 are as follows (detection results are as follows). Figure 1 As shown):

[0086] The active ingredients are: chlorogenic acid 0.22%, caffeic acid 0.086%, 4'-hydroxy-5-methoxy-7-O-β-D-glucopyranosyl dihydroflavone 7.34%, 1,5-O-dicaffeoylquinic acid 11.72%, 3,5-O-dicaffeoylquinic acid 11.72%, luteolin-4'-glucoside 4.15%, 4,5-O-dicaffeoylquinic acid 3.19%, 1,3,5-O-tricaffeoylquinic acid 0.1%, luteolin 1.5%, and 1,3,4-O-tricaffeoylquinic acid 10.13%. The total content of active ingredients is 50.16%.

[0087] Example 2

[0088] After being dried in the shade, *Gnaphalium affine* (origin: Jinhua, Zhejiang) was cut into sections, and 8.5 kg was weighed. This was mixed with an 80% (v / v) ethanol aqueous solution, with a herb-to-solvent mass-to-volume ratio of 1:20 (kg / L). The mixture was heated to 90℃ and refluxed four times, each time for 2 hours. The extracts were combined. The extract was concentrated under reduced pressure to 8.5 L (1.0 kg crude herb / L) to obtain a concentrated solution. The concentrated solution was centrifuged at 6000 rpm for 10 minutes, the precipitate was discarded, and the supernatant was collected.

[0089] The macroporous resin LS305, soaked in water, was packed into a column (9×76cm, 1 column volume ~5L); the supernatant was loaded onto the column at a flow rate of 0.5 column volumes / h until complete, and the eluent was discarded; then, 8 column volumes of 0.1% (v / v) formic acid aqueous solution were used to elute impurities at a flow rate of 1 column volume / h, and the resulting eluent was discarded; then, 8 column volumes of 80% (v / v) ethanol aqueous solution were used to elute at a flow rate of 1 column volume / h, and the eluent was collected; the eluent was concentrated by vacuum distillation and dried to obtain 240.0 g of resin eluent.

[0090] Take the above resin eluent, add ethyl acetate first at a ratio of 2:1 of ethyl acetate to ethanol, shake and mix well, then add ethanol, the total material-to-liquid ratio is 0.01 kg / L, shake and mix again, filter to obtain a first filtrate, then add ammonia water to the first filtrate so that the volume percentage of ammonia water to the first filtrate is 0.2%, shake and mix well, filter, the pH of the filtrate is 3.4, concentrate the filtrate under reduced pressure, dry, and obtain 78.6 g of Gnaphalium affine extract.

[0091] The active ingredients of the cudweed extract in Example 2 are as follows:

[0092] The active ingredients are: chlorogenic acid 0.125%, caffeic acid 0.04%, 4'-hydroxy-5-methoxy-7-O-β-D-glucopyranosyl dihydroflavone 7.33%, 1,5-O-dicaffeoylquinic acid 11.31%, 3,5-O-dicaffeoylquinic acid 14.40%, luteolin-4'-glucoside 4.08%, 4,5-O-dicaffeoylquinic acid 3.07%, 1,3,5-O-tricaffeoylquinic acid 0.1%, luteolin 1.58%, and 1,3,4-O-tricaffeoylquinic acid 10.07%. The total content of active ingredients is 52.11%.

[0093] Example 3

[0094] After being dried in the shade, *Gnaphalium affine* (origin: Quzhou, Zhejiang) was cut into sections, and 5 kg was weighed out. This was mixed with a 50% (v / v) ethanol aqueous solution, with a herb-to-solvent mass-to-volume ratio of 1:15 (kg / L). The mixture was heated at 120℃ and refluxed four times, each time for 2 hours. The extracts were combined. The extract was concentrated under reduced pressure to 7 L (0.7 kg crude herb / L) to obtain a concentrated solution. The concentrated solution was centrifuged at 4000 rpm for 15 minutes, the precipitate was discarded, and the supernatant was collected.

[0095] The macroporous resin LS305, soaked in water, was packed into a column (7×48cm, 1 column volume ~2.4L); the supernatant was loaded onto the column at a flow rate of 0.5 column volumes / h until complete, and the eluent was discarded; then, elution was carried out with 10 column volumes of 0.5% (v / v) formic acid aqueous solution at a flow rate of 1 column volume / h to remove impurities, and the resulting eluent was discarded; then, elution was carried out with 10 column volumes of 50% (v / v) ethanol aqueous solution at a flow rate of 1 column volume / h, and the eluent was collected; the eluent was concentrated by vacuum distillation and dried to obtain 182.6g of resin eluent.

[0096] Take the above resin eluent, add ethyl acetate first at a ratio of 1:1 of ethyl acetate to ethanol, shake and mix well, then add ethanol, with a total material-to-liquid ratio of 1 kg / L, shake and mix again, filter to obtain a first filtrate, then add ammonia water to the first filtrate to make the volume percentage of ammonia water to the first filtrate 0.05%, shake and mix well, filter, the pH of the filtrate is 3.3, concentrate the filtrate under reduced pressure, dry, and obtain 53.2 g of Gnaphalium affine extract.

[0097] The active ingredients of the cudweed extract in Example 3 are as follows (all percentages below are by mass):

[0098] The active ingredients are: chlorogenic acid 0.221%, caffeic acid 0.101%, 4'-hydroxy-5-methoxy-7-O-β-D-glucopyranosyl dihydroflavone 7.97%, 1,5-O-dicaffeoylquinic acid 12.10%, 3,5-O-dicaffeoylquinic acid 12.17%, luteolin-4'-glucoside 4.51%, 4,5-O-dicaffeoylquinic acid 3.42%, 1,3,5-O-tricaffeoylquinic acid 0.1%, luteolin 1.897%, and 1,3,4-O-tricaffeoylquinic acid 10.45%. The total content of active ingredients is 52.94%.

[0099] Comparative Example 1

[0100] After being dried in the shade, *Gnaphalium affine* (from Quzhou, Zhejiang) was cut into sections, and 5 kg was weighed out. This was mixed with a 60% (v / v) ethanol aqueous solution, with a herb-to-solvent mass-to-volume ratio of 1:15 (kg / L). The mixture was heated at 120℃ and refluxed four times, each time for 2 hours. The extracts were combined. The extract was concentrated under reduced pressure (60℃) to 5 L (herb:concentrate mass-to-volume ratio of 1:1 kg / L) to obtain a concentrated solution. Petroleum ether (boiling range 60–90℃) was added to the concentrated solution for extraction three times, with the volume ratio of concentrated solution to petroleum ether being 1:1 each time. The petroleum ether phase was discarded, yielding aqueous phase one (5 L). Ethyl acetate was added to aqueous phase one for extraction three times, with the volume ratio of aqueous phase one to ethyl acetate being 1:1 each time. After extraction, aqueous phase two (5 L) was obtained. Water-saturated n-butanol was added to aqueous phase two for extraction three times, with the volume ratio of aqueous phase two to water-saturated n-butanol being 1:1 each time. The ethyl acetate phase and the water-saturated n-butanol phase were combined and concentrated under reduced pressure (60°C) to dryness to obtain 249.6 g of the composition of the comparative example.

[0101] The active ingredients of the compositions in the comparative examples are as follows (all percentages below are by mass):

[0102] In the comparative example, GAD contained 1.54% chlorogenic acid, 0.15% caffeic acid, 5.31% 4'-hydroxy-5-methoxy-7-O-β-D-glucopyranosyl dihydroflavone, 6.44% 1,5-O-dicaffeoylquinic acid, 3.41% 3,5-O-dicaffeoylquinic acid, 1.91% luteolin-4'-glucoside, 2.14% 4,5-O-dicaffeoylquinic acid, 0.5% 1,3,5-O-tricaffeoylquinic acid, 0.13% luteolin, and 1.2% 1,3,4-O-tricaffeoylquinic acid. The total content of active ingredients was 22.73%.

[0103] In Example 1 of the patent "A Traditional Chinese Medicine Composition, Preparation Method Thereof, Kit and Application (CN 114053321 A)", the medicinal materials used were collected in Shangxi Town, Yiwu, Zhejiang Province in April 2018, with a total content of 10 active components of 3.62%, which is significantly higher than that of the medicinal materials in the batch of the present invention. The original extraction process obtained a composition with low content (22.73%) when the active component content of the medicinal materials was low, but the novel process of the present invention still obtained a Gnaphalium affine extract with an active component content of 50% or more under the condition of low active component content of the medicinal materials.

[0104] Effect Example 1

[0105] Hypouricemic Pharmacodynamic Experiment

[0106] For the Gnaphalium affine composition in the patent "A Traditional Chinese Medicine Composition, Preparation Method Thereof, Kit and Application (CN 114053321 A)", the effective dose in rats is 450 mg / kg (corresponding to a daily dose of 5 g for a 70 kg adult). The effective dose of the Gnaphalium affine extract obtained by the present invention in rats is 50 mg / kg (corresponding to a daily dose of 0.56 g for a 70 kg adult), and the effective dose is reduced by 9 times.

[0107] In the effect example of the present invention, 32 SD rats (200±20 g, purchased from Shanghai Sippr-BK Laboratory Animal Co., Ltd.; experimental animal production license number: SCXK (Shanghai) 2018-0006, animal quality certificate number 20180006050753) were used, which were raised in the Laboratory Animal Center of Shanghai Institute of Pharmaceutical Industry Co., Ltd. The feeding standards are as follows: room temperature 22±2°C, relative humidity 50±10%, 12-hour day-night alternation, and standard experimental feed and water are provided. The animals were fasted for 12 hours before the test, with free access to water. All animal experiments complied with the guidelines for the care and use of laboratory animals and were approved by the Animal Ethics Committee of Shanghai Institute of Pharmaceutical Industry Co., Ltd.

[0108] Experimental Method

[0109] Rat Model of Hyperuricemic Nephropathy and Administration Mode

[0110] Thirty-two SD rats were randomly divided into three groups of eight: a normal group, a hyperuricemic nephropathy model group, a benzbromarone (positive control, solvent 0.5% sodium carboxymethyl cellulose CMC-Na) 4.5 mg / kg group, and a gnaphalium affine extract (solvent 0.5% CMC-Na) 50 mg / kg group. The drug administration volume for each group was 0.1 mL / 10 g body weight. A hyperuricemic nephropathy model was established by daily gavage administration of a mixture of potassium oxonate (1.5 g / kg) and adenine (0.2 g / kg) (solvent: 0.5% CMC-Na) until the end of the experiment (day 31). Three days after modeling, starting from day 4, rats in the drug-treated group were administered the drug by gavage 1 hour after modeling, while rats in the normal group were administered the same volume of 0.5% CMC-Na by gavage. Blood samples of 1 mL were collected from each group at different time points (0 to 8 hours after administration) on days 11 (8 days of treatment), 18 (15 days of treatment), 25 (22 days of treatment), and 31 (28 days of treatment) after administration and placed in heparinized centrifuge tubes. After the blood samples were allowed to stand for 1 hour, they were centrifuged at 5000 rpm for 5 minutes at 4°C to separate the serum, which was then stored at -20°C for later use.

[0111] Determination of serum uric acid levels in rats

[0112] liquid phase conditions

[0113] A Waters XBridge Amide analytical column (4.6 mm × 250 mm, 3.5 μm) was used. The mobile phase was 0.5% acetic acid (A)-methanol (B), with isocratic elution: 0–10 min, 5% B, 10–20 min, 100% B, 20–30 min, 5% B; the flow rate was 1 mL / min; the column temperature was 30 °C; the detection wavelength was 288 nm; and the injection volume was 10 μL.

[0114] Preparation of uric acid standard solution

[0115] According to the method for preparing uric acid standard in the literature “Liu Xuyuan; Shang Qian; Li Chuan; Liu Peng; Liu Wei; Zhao Guilong; Zhou Zhixing; Zhang Haizhi; HPLC method for serum uric acid determination and related drug evaluation in mouse hyperuricemia model [J]. Drug Evaluation Research, 2017(03):319–323,” 25.00 mg of uric acid reference standard was accurately weighed into a 50 mL volumetric flask and diluted with 0.5% ammonia water to obtain a uric acid reference standard with a mass concentration of 500 ug / mL. It was then serially diluted to 200, 100, 80, 50, 20, 10, and 5 ug / mL.

[0116] Plasma sample pretreatment

[0117] Serum uric acid levels were determined by HPLC at different time points on days 11 (8 days of treatment), 18 (15 days of treatment), 25 (22 days of treatment), and 31 (28 days of treatment). 50 μL of plasma was precisely pipetted, 100 μL of methanol was added to precipitate proteins, the mixture was vortexed for 1 minute, and centrifuged at 14000 rpm for 10 minutes at 4°C. 100 μL of the supernatant was then injected into the HPLC for analysis.

[0118] Data Analysis

[0119] The area under the curve (AUC) of uric acid levels from 0 to 8 hours over time. 0-8 (h*mg / L) was calculated using a non-compartmental model in Phoenix 64 WinNonlin software. Data are expressed as mean ± standard deviation (Mean ± SD). If the data conforms to a normal distribution and the differences between different groups are equal, ANOVA parametric analysis is used, followed by Dunnett's multiple comparison test. P < 0.05, P < 0.01, and P < 0.001 are considered statistically significant.

[0120] Experimental results

[0121] Effects of oral administration of Gnaphalium affine extract on serum uric acid levels in rats

[0122] Table 1. Area under the time curve (AUC) of serum uric acid levels from 0 to 8 hours in different groups of animals at different drug administration cycles. 0-8 Changes in (h*mg / L).

[0123]

[0124] Note: Compared with the normal group: ***P<0.001, indicating extremely significant statistical difference; compared with the hyperuricemia nephropathy model group: ###P<0.001, ##P<0.01, indicating extremely significant statistical difference, #P<0.05, indicating significant statistical difference.

[0125] As shown in Table 1, compared with the normal group, the serum uric acid level in the hyperuricemic nephropathy model group was significantly increased one week after modeling (P<0.001), indicating successful model replication. Within four weeks of modeling, the serum uric acid level in the hyperuricemic nephropathy model group was also significantly increased (P<0.001), indicating the stability of the rat model of chronic hyperuricemic nephropathy. Compared with the hyperuricemic nephropathy model group, the increase in uric acid level in the positive control group (benzbromarone 4.5 mg / kg) was significantly inhibited at 15, 22, and 28 days after continuous administration (18, 25, and 31 days after modeling) (P<0.05, P<0.01), indicating that the positive control group benzbromarone has a uric acid-lowering effect on rats with hyperuricemic nephropathy. After continuous administration for 15 (18 days of modeling), 22 (25 days of modeling), and 28 (31 days of modeling) days, the serum uric acid levels in the 50 mg / kg *Gnaphalium affine* extract group were significantly lower than those in the hyperuricemic nephropathy group (P<0.05). The results indicate that the effective dose of *Gnaphalium affine* extract is as low as 50 mg / kg.

[0126] Example 2

[0127] Oral preparations (granules) made from cudweed extract.

[0128] Cudweed extract and lactose were mixed evenly in a 1:1 ratio, and a soft material was prepared using 80% ethanol as a wetting agent. The mixture was then sieved and dried to obtain cudweed extract granules. Those skilled in the art will know that the cudweed extract granules correspond to a daily dose of 1.1 g for a 70 kg adult.

[0129] Cudweed extract and lactose were mixed evenly in a 1:2 ratio, and a soft material was prepared using 70% ethanol as a wetting agent. The mixture was then sieved and dried to obtain cudweed extract granules. Those skilled in the art will know that the cudweed extract granules correspond to a daily dose of 1.7g for a 70kg adult.

[0130] Cudweed extract and lactose were mixed evenly in a 1:3 ratio, and a soft material was prepared using 60% ethanol as a wetting agent. The mixture was then sieved and dried to obtain cudweed extract granules. Those skilled in the art will know that the cudweed extract granules correspond to a daily dose of 2.2g for a 70kg adult.

[0131] Example 3

[0132] Dissolution test

[0133] The dissolution method II of the 2020 edition of the Chinese Pharmacopoeia was used, with 900 mL of artificial intestinal fluid at pH 6.8 as the dissolution medium, a rotation speed of 75 r / min, and a water bath temperature of (37.0±0.5)℃. 560 mg of *Gnaphalium affine* extract from Example 1, along with the *Gnaphalium affine* composition from Comparative Example 1 containing an equal amount of active ingredient and the LS305 resin eluent from Example 1 containing an equal amount of active ingredient, were accurately weighed and uniformly dispersed in the dissolution medium. Samples of 5.0 mL were taken at 5, 15, 30, 45, 60, and 90 min, respectively, with equal volumes and isothermal amounts of dissolution medium added simultaneously. The samples were filtered through a 0.22 μm microporous membrane before analysis. The results are shown in the table below.

[0134]

[0135]

[0136] The results showed that the dissolution rate and extent of the active ingredients were significantly better than those of the extract from *Gnaphalium affine* in Example 1 than that of the LS305 resin eluent in Example 1 than that of the composition from *Gnaphalium affine* in Comparative Example 1.

Claims

1. A pharmaceutical composition, characterized in that, It includes the following active ingredients in weight fractions: 0.1-0.3% chlorogenic acid, 0.01-0.15% caffeic acid, and 6-9% 4'-hydroxy-5-methoxy-7- O-β -D-glucopyranosyl dihydroflavonoids, 9-14% 1,5-O-dicaffeoylquinic acid, 10-15% 3,5-O-dicaffeoylquinic acid, 3.5-5% luteolin-4'-glucoside, 2.5-4% 4,5-O-dicaffeoylquinic acid, 0.01-0.2% 1,3,5-O-tricaffeoylquinic acid, 1-2% luteolin and 8-12% 1,3,4-O-tricaffeoylquinic acid; The pharmaceutical composition is prepared by the following method, which includes the following steps: The ethanol-water extract of Gnaphalium affine was obtained by extracting Gnaphalium affine with aqueous ethanol solution. After concentration under reduced pressure, the extract was centrifuged, and the supernatant was collected. The supernatant was purified by column chromatography and dried to obtain crude extract of Gnaphalium affine. Take the crude extract of Cnidium monnieri, first add ethyl acetate, mix well, then add ethanol, mix again to obtain an ethyl acetate / ethanol mixed solution of the crude extract of Cnidium monnieri; filter the ethyl acetate / ethanol mixed solution of the crude extract of Cnidium monnieri to obtain a first filtrate. The primary filtrate is mixed with ammonia water, filtered to obtain a secondary filtrate, and dried to obtain a pharmaceutical composition. The active ingredient content of the crude cudweed extract is 25-27%.

2. The pharmaceutical composition according to claim 1, characterized in that, It meets one or more of the following conditions: (1) The mass fraction of chlorogenic acid is 0.125-0.221%; (2) The mass fraction of the caffeic acid is 0.04-0.101%; (3) The 4'-hydroxy-5-methoxy-7- O-β The mass fraction of -D-glucopyranosyl dihydroflavonoids is 7.33%-7.97%; (4) The mass fraction of the 1,5-O-dicaffeoylquinic acid is 11.31-12.1%; (5) The mass fraction of the 3,5-O-dicaffeoylquinic acid is 11.72-14.4%; (6) The mass fraction of the luteolin-4'-glucoside is 4.08-4.51%; (7) The mass fraction of the 4,5-O-dicaffeoylquinic acid is 3.07-3.42%; (8) The mass fraction of the 1,3,5-O-tricaffeoylquinic acid is 0.05%-0.15%; (9) The mass fraction of luteolin is 1.5-1.897%; (10) The mass fraction of the 1,3,4-O-tricaffeoylquinic acid is 10.07-10.45%; (11) The active ingredient content of the pharmaceutical composition is 50%-70%.

3. The pharmaceutical composition according to claim 2, characterized in that, It meets one or more of the following conditions: (1) The mass fraction of chlorogenic acid is 0.125%, 0.22%, or 0.221%; (2) The mass fraction of caffeic acid is 0.04%, 0.086%, or 0.101%; (3) The 4'-hydroxy-5-methoxy-7- O-β The mass fractions of -D-glucopyranosyl dihydroflavonoids were 7.33%, 7.34%, or 7.97%. (4) The mass fraction of the 1,5-O-dicaffeoylquinic acid is 11.31%, 11.72%, or 12.1%; (5) The mass fraction of the 3,5-O-dicaffeoylquinic acid is 11.725%, 12.17%, or 14.4%; (6) The mass fraction of the luteolin-4'-glucoside is 4.08%, 4.15%, or 4.51%; (7) The mass fraction of the 4,5-O-dicaffeoylquinic acid is 3.07%, 3.19%, or 3.42%; (8) The mass fraction of the 1,3,5-O-tricaffeoylquinic acid is 0.1%; (9) The mass fraction of luteolin is 1.5%, 1.58% or 1.897%; (10) The mass fraction of the 1,3,4-O-tricaffeoylquinic acid is 10.07%, 10.13%, or 10.45%; (11) The active ingredient content of the pharmaceutical composition is 50.16%, 52.11% or 52.94%.

4. The pharmaceutical composition according to claim 1, characterized in that, The active ingredient of the pharmaceutical composition comprises 0.1-0.3% chlorogenic acid, 0.04-0.101% caffeic acid, and 6-8% 4'-hydroxy-5-methoxy-7- O-β Composed of -D-pyranoglosyl dihydroflavonoid, 9-14% 1,5-O-dicaffeoylquinic acid, 10-15% 3,5-O-dicaffeoylquinic acid, 3.5-5% luteolin-4'-glucoside, 2.5-4% 4,5-O-dicaffeoylquinic acid, 0.01-0.2% 1,3,5-O-tricaffeoylquinic acid, 1-2% luteolin and 8-12% 1,3,4-O-tricaffeoylquinic acid.

5. The pharmaceutical composition according to claim 1, characterized in that, The pharmaceutical composition is Option 1, Option 2, or Option 3; Option 1: The active ingredients of the pharmaceutical composition consist of 0.22% chlorogenic acid, 0.086% caffeic acid, and 4'-hydroxy-5-methoxy-7- O-β The composition consists of 7.34% D-pyranoglutenyl dihydroflavonoid, 11.72% 1,5-O-dicaffeoylquinic acid, 11.72% 3,5-O-dicaffeoylquinic acid, 4.15% luteolin-4'-glucoside, 3.19% 4,5-O-dicaffeoylquinic acid, 0.1% 1,3,5-O-tricaffeoylquinic acid, 1.5% luteolin, and 10.13% 1,3,4-O-tricaffeoylquinic acid. Option 2: The active ingredients of the pharmaceutical composition consist of 0.125% chlorogenic acid, 0.04% caffeic acid, and 4'-hydroxy-5-methoxy-7- O-β The composition consists of 7.33% D-pyranoglutenyl dihydroflavonoid, 11.31% 1,5-O-dicaffeoylquinic acid, 14.40% 3,5-O-dicaffeoylquinic acid, 4.08% luteolin-4'-glucoside, 3.07% 4,5-O-dicaffeoylquinic acid, 0.1% 1,3,5-O-tricaffeoylquinic acid, 1.58% luteolin, and 10.07% 1,3,4-O-tricaffeoylquinic acid. Option 3: The active ingredients of the pharmaceutical composition consist of 0.221% chlorogenic acid, 0.101% caffeic acid, and 4'-hydroxy-5-methoxy-7- O-β The composition consists of 7.97% D-pyranoglutenyl dihydroflavonoid, 12.10% 1,5-O-dicaffeoylquinic acid, 12.17% 3,5-O-dicaffeoylquinic acid, 4.51% luteolin-4'-glucoside, 3.42% 4,5-O-dicaffeoylquinic acid, 0.1% 1,3,5-O-tricaffeoylquinic acid, 1.897% luteolin, and 10.45% 1,3,4-O-tricaffeoylquinic acid.

6. The pharmaceutical composition according to claim 1, characterized in that, The preparation method satisfies one or more of the following conditions: (1) In the ethyl acetate / ethanol mixed solution, the volume ratio of ethyl acetate to ethanol is 0.5:1-5:1; (2) The concentration of the ethyl acetate / ethanol mixed solution of the crude extract of *Gnaphalium affine* is 0.005-1.5 kg / L; (3) NH3 in the ammonia water The mass fraction of H2O is 25-28%; (4) The volume percentage of the ammonia water to the primary filtrate is 0.03-0.3%; (5) The pH of the secondary filtrate is 3-4.

7. The pharmaceutical composition according to claim 6, characterized in that, The preparation method satisfies one or more of the following conditions: (1) In the ethyl acetate / ethanol mixed solution, the volume ratio of ethyl acetate to ethanol is 1:1-4:1; (2) The concentration of the ethyl acetate / ethanol mixed solution of the crude extract of *Gnaphalium affine* is 0.01-1 kg / L; (3) The volume percentage of the ammonia water to the primary filtrate is 0.05-0.2%; (4) The pH of the secondary filtrate is 3.3-3.

6.

8. The pharmaceutical composition according to claim 7, characterized in that, The preparation method satisfies one or more of the following conditions: (1) In the ethyl acetate / ethanol mixed solution, the volume ratio of ethyl acetate to ethanol is 1:1, 2:1 or 4:1; (2) The concentration of the ethyl acetate / ethanol mixed solution of the crude extract of Gnaphalium affine is 0.01 kg / L, 0.1 kg / L or 1 kg / L; (3) The volume percentage of the ammonia water to the primary filtrate is 0.05%, 0.15%, or 0.2%; (4) The pH of the secondary filtrate is 3.3, 3.4, and 3.

6.

9. The pharmaceutical composition according to claim 1, characterized in that, The preparation method of the crude extract of Gnaphalium affine satisfies one or more of the following conditions: (1) The volume content of ethanol in the ethanol aqueous solution is 50%-80%; (2) The mass-to-volume ratio of the cudweed to the ethanol aqueous solution is 1:10 to 1:20 kg / L; (3) The extraction temperature is 80–130℃; (4) The extraction is performed 2 to 4 times; (5) In the extraction process, the extraction time for a single extraction is 1 to 2 hours; (6) The mass-to-volume ratio of the cudweed to the concentrated liquid is 0.3–1.3 kg / L; (7) The centrifugal speed is 2000-8000 rpm; (8) The centrifugation time is 5-30 min; (9) The column chromatography uses macroporous resin LS305 for column packing; (10) The column chromatography uses an aqueous solution of organic acid to remove impurities.

10. The pharmaceutical composition according to claim 9, characterized in that, The preparation method of the crude extract of Gnaphalium affine satisfies one or more of the following conditions: (1) The volume content of ethanol in the ethanol-water solution is 60%; (2) The mass-to-volume ratio of the cudweed to the ethanol aqueous solution is 1:10 to 1:15 kg / L; (3) The extraction temperature is 90–120°C; (4) The extraction is performed 3 to 4 times; (5) The mass-to-volume ratio of the cudweed to the concentrated liquid is 0.5–1.0 kg / L; (6) The centrifugal speed is 3000-6000 rpm; (7) The centrifugation time is 10-20 min; (8) The column chromatography is eluted with an aqueous ethanol solution to obtain the eluent; (9) The mass-to-volume ratio of the *Gnaphalium affine* to the chromatography column used in the column chromatography is 1-2.5 kg / L; (10) The macroporous resin LS305 is a macroporous resin LS305 that has been soaked in water; (11) The supernatant loading flow rate is 0.3-1 column volume / h.

11. The pharmaceutical composition of claim 10, characterized in that, The preparation method of the crude extract of Gnaphalium affine satisfies one or more of the following conditions: (1) The extraction temperature is 90-100℃; (2) The temperature for vacuum concentration is 50–70°C; (3) The mass-to-volume ratio of the cudweed to the concentrated liquid is 0.5 kg / L, 0.7 kg / L, or 1.0 kg / L; (4) The centrifugation speed is 3000 rpm, 4000 rpm or 6000 rpm; (5) The centrifugation time is 10 min, 15 min or 20 min; (6) The mass-to-volume ratio of the *Gnaphalium affine* to the chromatography column used in the column chromatography is 1.1-2.1 kg / L; (7) The supernatant loading flow rate is 0.5 column volume / h.

12. The pharmaceutical composition according to claim 11, characterized in that, The vacuum concentration temperature is 60°C.

13. The pharmaceutical composition according to claim 12, characterized in that, The preparation method of the crude extract of Gnaphalium affine satisfies one or more of the following conditions: (1) The organic acid aqueous solution is an aqueous solution of formic acid or an aqueous solution of acetic acid; (2) The volume content of the organic acid in the organic acid aqueous solution is 0.3%-0.7%; (3) The volume of the organic acid aqueous solution is 3-12 times the volume of the chromatography column; (4) The flow rate of the organic acid aqueous solution for impurity removal is 0.6-1.4 column volumes / h; (5) The volume content of ethanol in the ethanol-water solution is 50%-80%; (6) The volume of the ethanol-water solution is 3-12 times the volume of the chromatography column; (7) The elution flow rate of the ethanol aqueous solution is 0.6-1.4 column volumes / h.

14. The pharmaceutical composition according to claim 13, characterized in that, The preparation method of the crude extract of Gnaphalium affine satisfies one or more of the following conditions: (1) The organic acid aqueous solution is formic acid aqueous solution; (2) The volume content of the organic acid in the organic acid aqueous solution is 0.5%; (3) The volume of the organic acid aqueous solution is 5-10 times the volume of the chromatography column; (4) The flow rate of the organic acid aqueous solution for impurity removal is 1 column volume / h; (5) The volume content of ethanol in the ethanol-water solution is 60%; (6) The volume of the ethanol-water solution is 5-10 times the volume of the chromatography column; (7) The elution flow rate of the ethanol-water solution is 1 column volume / h.

15. A method for purifying a pharmaceutical composition according to any one of claims 1-14, characterized in that, It includes the following steps: The ethanol-water extract of Gnaphalium affine was obtained by extracting Gnaphalium affine with aqueous ethanol solution. After concentration under reduced pressure, the extract was centrifuged, and the supernatant was collected. The supernatant was purified by column chromatography and dried to obtain crude extract of Gnaphalium affine. Take the crude extract of Gnaphalium affine, first add ethyl acetate, mix well, then add ethanol, mix again to obtain an ethyl acetate / ethanol mixed solution of crude extract of Gnaphalium affine. The ethyl acetate / ethanol mixture of crude cudweed extract was filtered to obtain a primary filtrate. The primary filtrate is mixed with ammonia water, filtered to obtain a secondary filtrate, and dried to obtain a pharmaceutical composition. The active ingredient content of the crude cudweed extract is 25-27%.

16. The refining method as described in claim 15, characterized in that, The refining method satisfies one or more of the following conditions: (1) In the ethyl acetate / ethanol mixed solution, the volume ratio of ethyl acetate to ethanol is 0.5:1-5:1; (2) The concentration of the ethyl acetate / ethanol mixed solution of the crude extract of *Gnaphalium affine* is 0.005-1.5 kg / L; (3) NH3 in the ammonia water The mass fraction of H2O is 25-28%; (4) The volume percentage of the ammonia water to the primary filtrate is 0.03-0.3%; (5) The pH of the secondary filtrate is 3-4.

17. The refining method as described in claim 16, characterized in that, The refining method satisfies one or more of the following conditions: (1) In the ethyl acetate / ethanol mixed solution, the volume ratio of ethyl acetate to ethanol is 1:1-4:1; (2) The concentration of the ethyl acetate / ethanol mixed solution of the crude extract of *Gnaphalium affine* is 0.01-1 kg / L; (3) The volume percentage of the ammonia water to the primary filtrate is 0.05-0.2%; (4) The pH of the secondary filtrate is 3.3-3.

6.

18. The refining method as described in claim 17, characterized in that, The refining method satisfies one or more of the following conditions: (1) In the ethyl acetate / ethanol mixed solution, the volume ratio of ethyl acetate to ethanol is 1:1, 2:1 or 4:1; (2) The concentration of the ethyl acetate / ethanol mixed solution of the crude extract of Gnaphalium affine is 0.01 kg / L, 0.1 kg / L or 1 kg / L; (3) The volume percentage of the ammonia water to the primary filtrate is 0.05%, 0.15%, or 0.2%; (4) The pH of the secondary filtrate is 3.3, 3.4, and 3.

6.

19. The refining method as described in claim 15, characterized in that, The preparation method of the crude extract of Gnaphalium affine satisfies one or more of the following conditions: (1) The volume content of ethanol in the ethanol aqueous solution is 50%-80%; (2) The mass-to-volume ratio of the cudweed to the ethanol aqueous solution is 1:10 to 1:20 kg / L; (3) The extraction temperature is 80–130℃; (4) The extraction is performed 2 to 4 times; (5) In the extraction process, the extraction time for a single extraction is 1 to 2 hours; (6) The mass-to-volume ratio of the cudweed to the concentrated liquid is 0.3–1.3 kg / L; (7) The centrifugal speed is 2000-8000 rpm; (8) The centrifugation time is 5-30 min; (9) The column chromatography uses macroporous resin LS305 for column packing; (10) The column chromatography uses an aqueous solution of organic acid to remove impurities.

20. The refining method as described in claim 19, characterized in that, The preparation method of the crude extract of Gnaphalium affine satisfies one or more of the following conditions: (1) The volume content of ethanol in the ethanol-water solution is 60%; (2) The mass-to-volume ratio of the cudweed to the ethanol aqueous solution is 1:10 to 1:15 kg / L; (3) The extraction temperature is 90–120°C; (4) The extraction is performed 3 to 4 times; (5) The mass-to-volume ratio of the cudweed to the concentrated liquid is 0.5–1.0 kg / L; (6) The centrifugal speed is 3000-6000 rpm; (7) The centrifugation time is 10-20 min; (8) The column chromatography is eluted with an aqueous ethanol solution to obtain the eluent; (9) The mass-to-volume ratio of the *Gnaphalium affine* to the chromatography column used in the column chromatography is 1-2.5 kg / L; (10) The macroporous resin LS305 is a macroporous resin LS305 that has been soaked in water; (11) The supernatant loading flow rate is 0.3-1 column volume / h.

21. The refining method as described in claim 20, characterized in that, The preparation method of the crude extract of Gnaphalium affine satisfies one or more of the following conditions: (1) The extraction temperature is 90-100℃; (2) The temperature for vacuum concentration is 50–70°C; (3) The mass-to-volume ratio of the cudweed to the concentrated liquid is 0.5 kg / L, 0.7 kg / L, or 1.0 kg / L; (4) The centrifugation speed is 3000 rpm, 4000 rpm or 6000 rpm; (5) The centrifugation time is 10 min, 15 min or 20 min; (6) The mass-to-volume ratio of the *Gnaphalium affine* to the chromatography column used in the column chromatography is 1.1-2.1 kg / L; (7) The supernatant loading flow rate is 0.5 column volume / h.

22. The refining method as described in claim 21, characterized in that, The vacuum concentration temperature is 60°C.

23. The refining method as described in claim 22, characterized in that, The preparation method of the crude extract of Gnaphalium affine satisfies one or more of the following conditions: (1) The organic acid aqueous solution is an aqueous solution of formic acid or an aqueous solution of acetic acid; (2) The volume content of the organic acid in the organic acid aqueous solution is 0.3%-0.7%; (3) The volume of the organic acid aqueous solution is 3-12 times the volume of the chromatography column; (4) The flow rate of the organic acid aqueous solution for impurity removal is 0.6-1.4 column volumes / h; (5) The volume content of ethanol in the ethanol-water solution is 50%-80%; (6) The volume of the ethanol-water solution is 3-12 times the volume of the chromatography column; (7) The elution flow rate of the ethanol aqueous solution is 0.6-1.4 column volumes / h.

24. The refining method as described in claim 23, characterized in that, The preparation method of the crude extract of Gnaphalium affine satisfies one or more of the following conditions: (1) The organic acid aqueous solution is formic acid aqueous solution; (2) The volume content of the organic acid in the organic acid aqueous solution is 0.5%; (3) The volume of the organic acid aqueous solution is 5-10 times the volume of the chromatography column; (4) The flow rate of the organic acid aqueous solution for impurity removal is 1 column volume / h; (5) The volume content of ethanol in the ethanol-water solution is 60%; (6) The volume of the ethanol-water solution is 5-10 times the volume of the chromatography column; (7) The elution flow rate of the ethanol-water solution is 1 column volume / h.

25. A pharmaceutical preparation, characterized in that, It comprises a pharmaceutical composition as described in any one of claims 1-14 and an acceptable pharmaceutical excipient, said pharmaceutical excipient including lactose, and / or, said formulation is an oral granule formulation.

26. The pharmaceutical formulation as described in claim 25, characterized in that, The mass ratio of the pharmaceutical composition to the lactose is 1:1 to 1:

5.

27. The pharmaceutical formulation as described in claim 26, characterized in that, The mass ratio of the pharmaceutical composition to the lactose is 1:1 to 1:

3.

28. The pharmaceutical formulation of claim 27, characterized in that, The mass ratio of the pharmaceutical composition to the lactose is 1:1, 1:2, or 1:

3.

29. The pharmaceutical formulation as described in claim 28, characterized in that, It is prepared by mixing the pharmaceutical composition, lactose and humectant, sieving and drying.

30. The pharmaceutical formulation as described in claim 29, characterized in that, The preparation satisfies one or two of the following conditions: (1) The wetting agent is a 50%-90% aqueous ethanol solution; (2) The mass ratio of the pharmaceutical composition to the wetting agent is 5% to 15%.

31. The pharmaceutical formulation according to claim 30, characterized in that, The wetting agent is a 60%-80% aqueous ethanol solution.

32. Use of a pharmaceutical composition as described in any one of claims 1-14, or a pharmaceutical preparation as described in any one of claims 25-31, in the preparation of a medicament for treating chronic hyperuricemia or hyperuricemic nephropathy.

Citation Information

Patent Citations

  • Traditional Chinese medicine composition, preparation method, kit and application thereof

    CN114053321A

  • Mongolian cudweed extract solid dispersion as well as preparation method and application thereof

    CN118557617A